vs

Side-by-side financial comparison of AVADEL PHARMACEUTICALS PLC (AVDL) and Plymouth Industrial REIT, Inc. (PLYM). Click either name above to swap in a different company.

AVADEL PHARMACEUTICALS PLC is the larger business by last-quarter revenue ($77.5M vs $51.2M, roughly 1.5× Plymouth Industrial REIT, Inc.). AVADEL PHARMACEUTICALS PLC runs the higher net margin — 0.0% vs -106.3%, a 106.3% gap on every dollar of revenue. On growth, AVADEL PHARMACEUTICALS PLC posted the faster year-over-year revenue change (54.9% vs -1.4%). Over the past eight quarters, AVADEL PHARMACEUTICALS PLC's revenue compounded faster (99.6% CAGR vs 0.4%).

Avadel Pharmaceuticals, is an Irish specialty pharmaceutical company that focuses on sleep disorder medicines. Avadel markets products in the hospital and primary care spaces. The company is headquartered in Dublin, Ireland with operations in St. Louis, Missouri and Lyon, France.

Plymouth Industrial REIT, Inc. is a real estate investment trust focused on owning, operating, and acquiring high-quality industrial properties including distribution centers, warehouses, and light industrial facilities across key U.S. logistics hubs. It serves tenants in e-commerce, retail, manufacturing, and third-party logistics sectors, supporting diverse business supply chain needs.

AVDL vs PLYM — Head-to-Head

Bigger by revenue
AVDL
AVDL
1.5× larger
AVDL
$77.5M
$51.2M
PLYM
Growing faster (revenue YoY)
AVDL
AVDL
+56.2% gap
AVDL
54.9%
-1.4%
PLYM
Higher net margin
AVDL
AVDL
106.3% more per $
AVDL
0.0%
-106.3%
PLYM
Faster 2-yr revenue CAGR
AVDL
AVDL
Annualised
AVDL
99.6%
0.4%
PLYM

Income Statement — Q3 FY2025 vs Q3 FY2025

Metric
AVDL
AVDL
PLYM
PLYM
Revenue
$77.5M
$51.2M
Net Profit
$20.0K
$-54.4M
Gross Margin
Operating Margin
2.5%
-102.5%
Net Margin
0.0%
-106.3%
Revenue YoY
54.9%
-1.4%
Net Profit YoY
100.8%
-248.5%
EPS (diluted)
$0.00
$-1.23

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
AVDL
AVDL
PLYM
PLYM
Q3 25
$77.5M
$51.2M
Q2 25
$68.1M
$47.2M
Q1 25
$52.5M
$45.6M
Q4 24
$50.4M
$47.6M
Q3 24
$50.0M
$51.9M
Q2 24
$41.5M
$48.7M
Q1 24
$27.2M
$50.2M
Q4 23
$19.5M
$50.8M
Net Profit
AVDL
AVDL
PLYM
PLYM
Q3 25
$20.0K
$-54.4M
Q2 25
$9.7M
$-6.1M
Q1 25
$-4.9M
$5.8M
Q4 24
$-5.0M
$147.4M
Q3 24
$-2.6M
$-15.6M
Q2 24
$-13.8M
$1.3M
Q1 24
$-27.3M
$6.2M
Q4 23
$-28.8M
$9.3M
Gross Margin
AVDL
AVDL
PLYM
PLYM
Q3 25
Q2 25
90.7%
Q1 25
89.4%
Q4 24
90.5%
Q3 24
87.7%
Q2 24
93.3%
Q1 24
94.4%
Q4 23
96.4%
Operating Margin
AVDL
AVDL
PLYM
PLYM
Q3 25
2.5%
-102.5%
Q2 25
13.0%
-10.3%
Q1 25
-5.7%
Q4 24
-6.5%
Q3 24
-0.7%
-29.6%
Q2 24
-30.7%
2.7%
Q1 24
-95.8%
Q4 23
-128.0%
Net Margin
AVDL
AVDL
PLYM
PLYM
Q3 25
0.0%
-106.3%
Q2 25
14.2%
-12.9%
Q1 25
-9.4%
12.8%
Q4 24
-10.0%
309.9%
Q3 24
-5.2%
-30.1%
Q2 24
-33.3%
2.7%
Q1 24
-100.6%
12.4%
Q4 23
-148.0%
18.3%
EPS (diluted)
AVDL
AVDL
PLYM
PLYM
Q3 25
$0.00
$-1.23
Q2 25
$0.10
$-0.14
Q1 25
$-0.05
$0.13
Q4 24
$-0.04
$3.24
Q3 24
$-0.03
$-0.35
Q2 24
$-0.14
$0.03
Q1 24
$-0.30
$0.14
Q4 23
$-0.28
$0.21

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
AVDL
AVDL
PLYM
PLYM
Cash + ST InvestmentsLiquidity on hand
$91.6M
Total DebtLower is stronger
Stockholders' EquityBook value
$98.2M
$470.1M
Total Assets
$199.4M
$1.6B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
AVDL
AVDL
PLYM
PLYM
Q3 25
$91.6M
Q2 25
$81.5M
Q1 25
$66.5M
Q4 24
$73.8M
Q3 24
$65.8M
Q2 24
$71.4M
Q1 24
$88.8M
Q4 23
$105.1M
Total Debt
AVDL
AVDL
PLYM
PLYM
Q3 25
Q2 25
Q1 25
Q4 24
$646.4M
Q3 24
Q2 24
Q1 24
Q4 23
$873.4M
Stockholders' Equity
AVDL
AVDL
PLYM
PLYM
Q3 25
$98.2M
$470.1M
Q2 25
$90.7M
$539.6M
Q1 25
$74.1M
$571.0M
Q4 24
$73.8M
$579.5M
Q3 24
$74.7M
$436.5M
Q2 24
$70.3M
$475.2M
Q1 24
$78.4M
$484.6M
Q4 23
$87.7M
$483.0M
Total Assets
AVDL
AVDL
PLYM
PLYM
Q3 25
$199.4M
$1.6B
Q2 25
$187.2M
$1.6B
Q1 25
$167.9M
$1.4B
Q4 24
$164.2M
$1.4B
Q3 24
$158.3M
$1.5B
Q2 24
$157.5M
$1.4B
Q1 24
$167.9M
$1.4B
Q4 23
$164.7M
$1.4B
Debt / Equity
AVDL
AVDL
PLYM
PLYM
Q3 25
Q2 25
Q1 25
Q4 24
1.12×
Q3 24
Q2 24
Q1 24
Q4 23
1.81×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
AVDL
AVDL
PLYM
PLYM
Operating Cash FlowLast quarter
$22.2M
$20.0M
Free Cash FlowOCF − Capex
$22.2M
FCF MarginFCF / Revenue
28.7%
Capex IntensityCapex / Revenue
0.0%
Cash ConversionOCF / Net Profit
1110.25×
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
AVDL
AVDL
PLYM
PLYM
Q3 25
$22.2M
$20.0M
Q2 25
$12.7M
$23.4M
Q1 25
$-8.2M
$15.6M
Q4 24
$7.9M
$96.1M
Q3 24
$-6.9M
$17.6M
Q2 24
$-18.2M
$19.9M
Q1 24
$-29.7M
$16.6M
Q4 23
$-28.0M
$18.6M
Free Cash Flow
AVDL
AVDL
PLYM
PLYM
Q3 25
$22.2M
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24
Q4 23
FCF Margin
AVDL
AVDL
PLYM
PLYM
Q3 25
28.7%
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24
Q4 23
Capex Intensity
AVDL
AVDL
PLYM
PLYM
Q3 25
0.0%
Q2 25
Q1 25
Q4 24
Q3 24
0.0%
Q2 24
Q1 24
Q4 23
Cash Conversion
AVDL
AVDL
PLYM
PLYM
Q3 25
1110.25×
Q2 25
1.31×
Q1 25
2.67×
Q4 24
0.65×
Q3 24
Q2 24
15.12×
Q1 24
2.67×
Q4 23
2.01×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons